Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care
pharmafile | October 4, 2018 | News story | Research and Development | Mayo Clinic, baxter, kidney disease, pharma, renal
American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a bid to establish a “renal care centre of excellence” in the US.
The partnership marks the first launch of an initiative from the five-year Baxter and Mayo Clinic agreement signed in 2017 to drive innovation in areas of unmet need. The new centre will be based in Jacksonville, Florida at the Mayo Clinic Dialysis Center, a site which promises “state-of-the-art dialysis services in a comfortable, home-like facility”
The centre will offer a range of services including in-centre haemodialysis and outpatient dialysis services, as well as home dialysis training and support. It will also feature a Chronic Kidney Disease Clinic and a Nephrology Nutrition Clinic to provide all-encompassing care and dietary guidance to those with kidney disorders.
“The collaboration between Mayo Clinic and Baxter combines the best of our clinical, research and innovation expertise, and is rooted in the shared goal to improve the way we care for patients with serious and complex illnesses,” commented Dr Gianrico Farrugia, CEO of Mayo Clinic in Florida and president-elect of Mayo Clinic. “We are excited to establish this new renal care centre of excellence with Baxter.”
Laura Angelini, General Manager of Baxter’s Renal Care business, added: “We firmly believe there is a path to better care for kidney patients, which starts by managing the disease before dialysis is required and through simpler, more effective innovations. Our collaboration with Mayo Clinic will allow us to go even further in helping to establish transformative care.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
NHS England approves delayed-release treatment for rare kidney disease
NHS England has approved the routine commissioning of delayed-release mercaptamine bitartrate for eligible patients with …
